Back to search

University of Edinburgh

Advanced molecular imaging in the heart

Abstract

dc:description.abstract

INTRODUCTION: Molecular positron emission tomography (PET) visualises in real time the activity of a disease process. In theory, any disease process can be visualised, subject to the availability of a suitable radiolabelled tracer. Fibrosis and calcification are two of the most important disease processes underscoring the majority of cardiovascular pathologies encountered in clinical cardiology, with radiotracers targeting both these processes now available. This thesis focused on the role of hybrid PET in detecting and tracking myocardial fibrosis activity and fibroblast activation following myocardial infarction (MI) and in heart failure with a reduced ejection fraction (HFrEF) and recreating the clinical imaging conditions of calcific bioprosthetic valvular degeneration with a phantom model, alongside validation and optimisation of these imaging techniques. METHODS: PET/cardiovascular magnetic resonance (CMR) studies. Patients with recent (<1 week) and prior (>2 years) ST-segment elevation MI and patients with chronic (>3 months) HFrEF were recruited and compared with age- and sex- matched healthy volunteer participants. All participants underwent assessment of myocardial fibroblast activation, as a marker of fibrosis activity, by gallium-68 fibroblast activation protein inhibitor (68Ga-FAPI-46) PET/MR. A subset of HFrEF patients returned for repeat PET/MR at 6 months, and all patients with recent ST-segment MI were invited for CMR at 12 months to assess a) changes in 68Ga-FAPI-46 and left ventricular functional parameters, and b) left ventricular remodelling. A subset of these studies was evaluated for intra-observer repeatability and inter-observer reproducibility. PET/computed tomography (CT) study. A realistic advanced cardiac phantom model was evaluated in serial scanning sessions to mimic the clinical imaging conditions of calcific bioprosthetic valvular degeneration. Calcification activity of the model was evaluated using 18-fluorine sodium fluoride (18F-NaF) PET/CT and comparison made with prior human imaging of the same condition. Low doses (0.4-1.6mBq) of excess clinical 18F-labelled tracer were injected into 3 regions of interest mimicking regions of calcification on the leaflet (small and large pocket; 0.04ml and 0.12ml respectively) and the native valve leaflet (ring lesion; 0.5ml) with 6.5mBq administered to the 750ml cardiac chamber to mimic background activity. RESULTS: PET/MR – myocardial infarction. 80 participants were studied: 40 with recent ST-elevation MI, 20 with prior MI, 20 healthy controls. Quantification of tracer uptake within the myocardium demonstrated excellent intra-observer repeatability and inter-observer reproducibility with very low bias, narrow limits of agreement, and interclass correlation coefficients of 0.92-1.00 and 0.93-0.99 within and between operators respectively. Myocardial 68Ga-FAPI-46 uptake was observed in the acute infarct and peri-infarct regions which exceeded the extent of late gadolinium enhancement (burden 27.812.4% versus 15.210.6% respectively, p<0.001), with a third of patients also demonstrating right ventricular involvement. Myocardial 68Ga-FAPI-46 uptake was most intense at 1 and 2 weeks before declining at 4 and 12 weeks (maximum target to background ratio [TBRmax] 4.01.1, 3.71.0, 3.10.8 and 2.70.7 respectively, p<0.001). Compared to control volunteers, increased 68Ga-FAPI-46 uptake was observed in those with prior (76 years ago) MI, but this was of lower intensity than in those with acute MI (TBRmax 1.20.1 versus 1.70.5 versus 4.01.1 respectively, p<0.001). The intensity of myocardial 68Ga-FAPI-46 uptake correlated with time from MI (r=-0.649) and the burden correlated with lower left ventricular ejection fraction (r=-0.606), higher indexed left ventricular end diastolic volume (r=0.572), and higher scar burden (r=0.871) at 1 year (p<0.001 for all). Increased 68Ga-FAPI-46 uptake in the remote myocardium was also associated with left ventricular dilatation and systolic dysfunction. PET/MR - heart failure with reduced ejection fraction. 42 participants were studied (21 with ischaemic cardiomyopathy [ICM], 21 with non-ischaemic cardiomyopathy [NICM]). Comparison was also drawn with the 20 prior MI and 20 healthy controls from the MI cohort. [68Ga]FAPI-46 uptake was observed in all patients with HFrEF (68Ga-FAPI-46 maximum standardised uptake value [SUVmax]1.5±0.3 versus 2.7±1.5 respectively, p<0.001). The most intense uptake was observed in patients with ICM in regions of established MI (SUVmax 3.16±1.12). In patients with NICM, diffuse lower intensity fibroblast activation (SUVmax 2.28±0.48) was observed with the highest signal in the basal septum irrespective of the presence of underlying late gadolinium enhancement. Patients with ICM displayed higher 68Ga-FAPI-46 uptake compared to patients with prior MI without heart failure (n=20) (SUVmax 3.16±1.12 versus 2.45±0.34, p=0.03) despite similar infarct sizes. The pattern and magnitude of 68Ga-FAPI-46 uptake was unchanged in 19 patients who underwent repeat imaging after 6 months. PET/CT studies. With a PET reconstruction time of 30 seconds valvular PET signal reflected human transaortic valve implantation imaging, including signal to noise ratio (SNR) (45.6 vs. 44.3) and TBRmax (6.5 vs. 4.1) for the small pocket valvular region of interest compared with the human case. Background noise within the cardiac chambers (10.2% vs 12.0%) was also comparable. The PET signal in the large pocket and ring lesion markedly exceeded comparable human imaging with short (30 s) reconstruction time. When reduced to 15 seconds this yielded PET signal for both small (TBRmax 5.4) and large (TBRmax 6.0) valvular regions of interest closest to human imaging (TBRmax 4.1), though SNR was lower than in human TAVI dysfunction (44.3, small pocket 13.9, large pocket 15.6). CONCLUSIONS: In 68Ga-FAPI-46 PET/MR we have for the first time a reliable method to non-invasively visualise fibroblast activation and fibrosis activity in real time within the left ventricle and beyond. This provides different and complimentary information to existing structural assessments of established scar and confers important prognostic implications in myocardial infarction and heart failure. Fibroblast activation represents an unmet therapeutic target in myocardial fibrosis, and 68Ga-FAPI-46 PET is an obvious method to investigate the efficacy of these therapies as they are developed and translated into man. Advanced phantom models can mimic highly complex cardiovascular conditions and may be used in future molecular PET research, including those investigating therapeutic interventions for fibrosis and calcification.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Barton, Anna Kate
Advisors dc:contributor.advisor
  • Newby, David
  • Dweck, Marc

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Barton, Anna Kate. Advanced molecular imaging in the heart. 2026. https://era.ed.ac.uk/handle/1842/44956